Queen's delight

Queen's Delight (Stillingia sylvatica): A Comprehensive Reference

1. Identity and Botanical Description

Accepted botanical name: Stillingia sylvatica L. (Linnaeus, 1767)

Family: Euphorbiaceae (the spurge family)

The genus Stillingia was established in 1767 by Carl Linnaeus and is named after Benjamin Stillingfleet (1702–1771), a British botanist and naturalist known for his contributions to early botanical literature and correspondence with Linnaeus. The specific epithet sylvatica derives from the Latin silvaticus, meaning "pertaining to woods" or "growing wild in forests," which alludes to the plant's preference for woodland and open forest edges in its native range.

Common names: Queen's Delight, Queen's Root, Yaw Root, Silver Leaf, Cockup Hat, Marcory, Racine Royale, Raíz de la Reina, and Stillingia. The terms "Queen's Delight" and "Queen's Root" originate in the 19th-century American herbal tradition, where the plant held a prominent place in medical practice.

Stillingia sylvatica belongs to the Euphorbiaceae family, sharing botanical relatives with castor bean and croton. This perennial herb grows wild across the southeastern United States, thriving in sandy, well-drained soils where it develops a deep taproot that concentrates the acrid, milky latex for which the genus is named.

Its distribution spans from southeastern Virginia southward to southern Florida and westward to southern Texas, with extensions into New Mexico, Kansas, Colorado, and inland disjuncts in Kentucky; it also occurs in the Mexican states of Coahuila, Michoacán, and Tamaulipas.

It is a perennial herb that grows profusely in the US, particularly around the Virginia and Florida coastlines, preferring sandy soil. It grows to four feet, producing leathery leaves, yellow flowers without petals, and three-lobed fruits. The species is monoecious: individual flowers are either male or female, but both sexes can be found on the same plant. The plant exudes an acrid white sap when damaged, a hallmark of many spurges.

The root is slenderly fusiform, reddish-brown externally, and longitudinally wrinkled. The drug has occurred usually in cut pieces of variable length, and from 0.5 to 3 centimetres in diameter. It breaks with a fibrous fracture, and has a light reddish-brown bark, from 0.5 to 4 millimetres thick, spongy and finely fibrous with numerous resin cells, easily separable from the porous, radiate wood. The drug has a distinct odour, and a bitter, acrid, and pungent taste.

Common Preparations and Dosage Forms

Herbal products typically use the large woody root and rhizome, sometimes labeled as "queen's root," "yaw root," or simply "Stillingia." Historically and currently, Queen's Delight has been prepared and sold in the following forms:

• Dried root / cut and sifted root: used for decoctions and infusions.
• Fluid extract (fluidextract): the Fluidextractum Stillingiae was official in the U.S.P. Stillingia root in No. 40 powder was exhausted with 49% alcohol, and the volume of the product adjusted so that 1 fluid part represented 1 part of drug.
• Tincture: alcoholic preparations of fresh or dried root remain in use in niche herbal practice.
• Homeopathic preparations: Stillingia sylvatica HPUS (Homeopathic Pharmacopoeia of the United States) is listed and has appeared in multi-ingredient homeopathic products.
• Compound formulas: In the 1800s, Stillingia root was a key ingredient in the "Compound Extract of Stillingia," a remedy marketed for syphilis, reflecting the era's experimental approach to medicine, where plant-based remedies were extensively tried for various diseases with mixed results.

2. Pharmacopoeial and Regulatory Status

The root of Stillingia sylvatica was official in the United States Pharmacopoeia (USP) until 1926, and remained in the National Formulary until 1947. The plant was included in the United States Pharmacopeia in the 19th century, highlighting its recognized medicinal value during that era. It has no current monograph in the USP, the European Pharmacopoeia, the WHO herbal monographs series, or the ESCOP monographs. It is not evaluated by the German Commission E. No government or pharmacopoeial body currently endorses its therapeutic use.

3. Traditional and Historical Use

3a. Native American Use

Historically, Stillingia sylvatica has been valued in traditional Native American medicine, particularly by the Cherokee, Seminole, and Creek tribes, who used root decoctions and infusions as an astringent, emetic, antidiarrheal, blood purifier, and treatment for skin conditions, venereal diseases, and pediatric ailments to strengthen infants and prevent lameness.

Native American tribes, particularly those in the southeastern regions, recognized Stillingia's powerful alterative properties long before European herbalists documented its use. The Creek and Choctaw nations used the root in purification rituals and as a specific remedy for skin eruptions believed to indicate internal toxicity.

A decoction of the root was used to treat bird sickness, diarrhoea, vomiting, and appetite loss in children and in adults. It was also used to treat menstruation sickness, yellow eyes, and skin weakness. A decoction or tincture of the root was also used to treat the worst forms of venereal disease.

Small pieces of the root were chewed in winter to support a healthy throat and upper respiratory system.

3b. Eclectic Medicine and 19th-Century American Practice

Stillingia was a key remedy in 19th-century American Eclectic medicine, where it was widely praised for its alterative and "blood-cleansing" abilities. Eclectic physicians recommended it for syphilis, skin eruptions, swollen glands, and chronic rheumatism. The Eclectic School, which emerged in the United States in the 1830s, arose from earlier botanical medicine movements and Native American herbal traditions. Practitioners primarily used plant-based drugs that were indigenous to the United States and developed a distinct "American materia medica."

Early American Eclectic physicians, including Harvey Wickes Felter and John Uri Lloyd, documented Stillingia as a primary alterative in their therapeutic protocols. Writing in the 1905 Materia Medica and Clinical Therapeutics, physician Fred J. Petersen classified it as follows: Properties: alterative, stimulant; in large doses cathartic and emetic. Indications: when throat is tumid, red, with glistening membrane and scanty secretion; in skin diseases of a moist, red, and irritable nature. Use: in chronic sore throat, ozaena, and laryngitis; in irritation of the mucous membrane of the larynx, pharynx, bronchi, and throat with deficient secretion; of value in bronchial cough of a croupy nature with little or no secretion; in syphilis and strumous conditions. It must however be prepared from the fresh root, as the dry root is inert.

It was often included in compound formulas alongside herbs like sarsaparilla, burdock, and poke root — other strong detoxifying and lymphatic agents. The name "queen's root" is thought to stem from its reputation as a "royal" remedy in the herbal apothecary, particularly in the treatment of reproductive and venereal diseases, including mercury poisoning associated with syphilis treatments.

It was also historically used for bronchial congestion, with some practitioners using it as an expectorant and respiratory stimulant in cases of chronic bronchitis or "torpid" lungs.

Stillingia was used by the Eclectic medical movement and is an optional ingredient in the controversial Hoxsey cancer formula. It has also been used in homeopathy.

A number of 19th-century studies were published on analysis of Stillingia root, while the plant has been largely ignored more recently, even though it remained in the National Formulary until 1947.

From the American Eclectic pharmacopoeial tradition, in large doses, stillingia vomits and purges, producing in many instances a peculiar, disagreeable burning sensation in the stomach or some portion of the alimentary canal, accompanied with prostration of the system. In lesser doses it is an alterative, exerting an influence over the secretory and lymphatic functions that is unsurpassed by few, if any, of the known alteratives.

3c. Popular and Folk Uses

Stillingia was historically used in North American folk medicine and Eclectic medicine as a blood purifier, lymphatic stimulant, and alterative — a class of herbs believed to gradually restore health and balance to the body, especially by improving detoxification and elimination pathways. Stillingia was primarily used to treat chronic skin conditions, syphilis, lymphatic stagnation, bronchitis, and liver congestion. Traditionally, it was also employed for chronic inflammatory diseases, scrofula (tubercular lymph node swelling), and joint issues.

Despite its popularity in early American herbalism, stillingia was known to cause side effects such as nausea, vomiting, burning in the throat, or diarrhea, particularly if used in high doses or in its fresh form. As a result, it was traditionally dried and combined with soothing demulcents to mitigate its intensity.

This herb is not often used in modern herbalism. The herb is potentially harsh and toxic in large or prolonged doses, especially on the gastrointestinal tract and mucous membranes, and because of this, it has largely fallen out of favor in mainstream herbal practice and is used cautiously by modern herbalists.

4. Key Chemical Constituents

Chemical constituents of interest elucidated from the plant include gnidilatidin and gnidilatin, prostatin and prostratin, silvacrol, stillingia Factors S1–S8, and stillingine. The plant also contains an essential oil, protein, resin, and tannin. Hydrogen cyanide has also been identified in stillingia oil.

From the 1911 British Pharmaceutical Codex entry, stillingia contains the acrid resin sylvacrol, an acrid fixed oil, 3 to 4 percent of volatile oil, 10 to 12 percent of tannin, starch, and calcium oxalate. A 19th-century Eclectic chemical analysis reported the root of Stillingia sylvatica contains tannin (11.6 per cent), gum, starch, volatile oil (3.25 per cent) of a strong, disagreeable odour, an acrid oil soluble in ether, an acid resin, and about 5 per cent of ash. According to one 19th-century source, an alkaloid, stillingine, is present, but this was doubted by E. G. Eberhardt in Lilly's Bulletin No. 17, November 1891.

4a. Diterpene Esters (Stillingia Factors S1–S8)

The most pharmacologically significant class of compounds in Stillingia sylvatica roots are the diterpene esters. From roots of Stillingia sylvatica (Euphorbiaceae), eight more or less irritant Stillingia factors S1–S8 were isolated and identified as diterpene esters of the daphnane and tigliane types, carrying saturated, polyunsaturated, or hydroxylated fatty acids.

Chemically, the root contains a mix of tannins, resins, volatile oil, fixed oil, and several potent diterpene esters (including prostratin-like compounds and "Stillingia factors" S1–S8). These diterpenes are strongly irritating to skin and mucous membranes and, in animal and cell studies, can act as tumor promoters. Hydrogen cyanide has also been detected in related stillingia oils, reinforcing concerns about toxicity.

4b. Prostratin

Among the most scientifically researched individual constituents is prostratin, a tigliane-type diterpene ester. Sources of prostratin include several plants in the Euphorbiaceae family, including Stillingia sylvatica roots, as confirmed by Adolf and Hecker in 1980. Although many phorbol esters promote tumor formation, prostratin is a non-tumorigenic compound with promise for treatment of the HIV/AIDS virus.

Studies have been conducted with prostratin. Prostratin has been identified in the plant, with synthetic versions of the protein kinase C (PKC) activator being evaluated in studies.

4c. Other Noteworthy Constituents

Further identified constituents include diterpene esters including prostatin and gnidilatidin, volatile oil, and tannins. Stillingia root also contains gums and starches among other minor constituents. The fixed oil (stillingia oil) has been studied by HPLC and contains a complex mixture of fatty acids.

5. Mechanisms of Action

5a. Irritant and Secretory Stimulation

Stillingia is a mild irritant to the mouth and stomach, and therefore acts reflexly as a sialagogue and expectorant. This irritant action on mucosal surfaces is attributed primarily to the diterpene ester content. In small doses, stillingia is thought to exert a stimulatory action on the lymphatic and secretory systems. In larger doses, stillingia can act as an emetic (inducing vomiting) and laxative.

5b. Protein Kinase C (PKC) Activation by Prostratin

The constituent prostratin is a non-tumor-promoting phorbol ester that functions as a PKC agonist. A subset of quiescent memory CD4 T cells harboring integrated but transcriptionally silent proviruses poses an insurmountable barrier to the eradication of HIV in infected patients. Induction of HIV gene expression in these latently infected cells by immune-activating agents has been proposed as one approach to confer sensitivity to antiretroviral therapy. Interest has focused on the non-tumor-promoting phorbol ester, prostratin, as a potential agent to activate latent HIV proviruses.

Mechanistically, prostratin effectively activates HIV gene expression in latently infected cells, and it acts by stimulating IKK-dependent phosphorylation and degradation of IκBα, leading to activation of the transcription factor NF-κB, which drives transcription of the latent HIV provirus.

5c. Diterpene Tumor Promotion / Co-carcinogenesis

The broader class of phorbol-type and tigliane-type diterpene esters found in the Euphorbiaceae family, including those in Stillingia sylvatica, are well-characterized co-carcinogens in experimental models. Cryptic cocarcinogens require metabolic activation by esterases or lipases to become directly acting promoters and/or stimulators of initiation; it is suspected that cocarcinogens of the diterpene ester type may play a role as possible carcinogenic risk factors of the human environment, especially as environmental promoters.

6. Scientific Evidence by Area of Use

The overarching finding across all areas of proposed use is a profound lack of clinical human evidence. There is no evidence to support use of stillingia to treat cancer, infections, or other medical conditions. There are no clinical data to support the use of this herb for any of the proposed claims. What follows is a structured account of the state of evidence, area by area.

6a. Syphilis and Venereal Disease

Traditional claim: Stillingia sylvatica was used by Native Americans for syphilis and as a cathartic, diuretic, laxative, and emetic. Stillingia was considered an alternative cure for syphilis by many of the Eclectic physicians in the 19th century.

Evidence status: There are no controlled clinical trials, cohort studies, or case series evaluating Stillingia sylvatica for syphilis or any other venereal disease. The historical use predates modern evidence-based methodology. No mechanistic data specific to anti-spirochetal activity has been reported in peer-reviewed literature. Evidence remains at the level of historical record only.

6b. Skin Conditions

Traditional claim: Stillingia was historically used in North American folk medicine and Eclectic medicine as a blood purifier, lymphatic stimulant, and alterative. Stillingia was primarily used to treat chronic skin conditions, syphilis, lymphatic stagnation, bronchitis, and liver congestion.

Evidence status: The root of Queen's Delight contains chemicals that are very irritating to the skin and thin tissues throughout the body, like the nose, mouth, and throat. No peer-reviewed clinical trials or observational human studies on any dermatological indication have been identified. The topical application of the fresh root juice is specifically associated with adverse effects rather than benefit (see Safety section). Evidence is absent for clinical use.

6c. Respiratory Conditions (Bronchitis, Laryngitis)

Traditional claim: It was also historically used for bronchial congestion, with some practitioners using it as an expectorant and respiratory stimulant in cases of chronic bronchitis or "torpid" lungs. In irritation of the mucous membrane of the larynx, pharynx, bronchi, and throat with deficient secretion; of value in bronchial cough of a croupy nature with little or no secretion.

Evidence status: People sometimes use Queen's Delight for bronchitis, constipation, hemorrhoids, and many other conditions, but there is no good scientific evidence to support these uses. No human clinical trials, systematic reviews, or well-designed observational studies on any respiratory indication have been published. Evidence is absent.

6d. Lymphatic System and "Blood Purification"

Traditional claim: Stillingia Root is considered especially effective for the lymphatic system. It has been used to rid the body of toxins and cleanse and purify the blood, as well as relieve bronchial complaints.

Evidence status: The concept of "blood purification" and lymphatic drainage stimulation as used in Eclectic medicine reflects a pre-modern physiological framework without direct correspondence to measurable clinical endpoints. No randomized controlled trials, human pharmacokinetic studies, or biomarker studies evaluating lymphatic or hepatic detoxification effects of Stillingia sylvatica have been published. Evidence is absent.

6e. Cancer

Claim context: Stillingia root is one of the ingredients in Hoxsey Herbal Therapy, which is promoted as an alternative cancer treatment.

In vitro evidence: Stillingia is known to contain chemicals called diterpene esters, toxic irritants that can cause swelling and inflammation. One lab experiment suggested that diterpene esters can halt the growth of cancer cells, but stillingia has not been studied in controlled models specifically attributable to the whole plant extract. In vitro studies have shown that diterpene esters have antitumor activity, but stillingia itself has not been evaluated.

Evidence status: Stillingia root is one of the ingredients in Hoxsey Herbal Therapy, which is promoted as an alternative cancer treatment. However, there is no medical evidence to support use of Stillingia to treat cancer, infections, or other medical conditions. The in vitro antitumor data applies to isolated diterpene ester compounds, not to Stillingia sylvatica root extract as administered clinically. Furthermore, the same diterpene ester class includes compounds that function as tumor promoters in animal models, representing a conflicting biological signal. Evidence is limited to in vitro experiments only, with no human clinical data.

6f. HIV Latency (Prostratin Research)

Research context: This is the area where the greatest volume of modern peer-reviewed research related to constituents of Stillingia sylvatica has accumulated, though it specifically concerns the isolated compound prostratin, not the whole plant or root preparation.

The latent reservoir of HIV-1 in quiescent T cells is thought to be a major obstacle to clearance of infection by highly active antiretroviral therapy (HAART). Thus, identification of agents that can induce expression of latent virus may, in the presence of HAART, allow elimination of the infected cells by the immune response.

Researchers characterized the effects of prostratin, a non-tumor-promoting phorbol ester, on primary human peripheral blood lymphocytes (PBLs) and assessed its ability to reactivate latent HIV infection. Prostratin stimulation alone did not induce proliferation of quiescent PBLs; however, it could provide a secondary signal in the context of T-cell receptor stimulation. While prostratin alone was not sufficient to allow de novo HIV infection, it efficiently reactivated HIV expression from latently infected cells. These data indicate that prostratin alone is able to specifically reactivate latent virus in the absence of cellular proliferation, making it an attractive candidate for further study as an adjunctive therapy for the elimination of the latent HIV reservoir.

The phorbol ester prostratin stimulates HIV-1 expression in latently infected T-lymphoid and myeloid cell lines, but also in primary cells, with minimal effects on the immune system. However, the suitability of prostratin for use in humans is still unknown.

Evidence status: The prostratin research is promising at the in vitro and ex vivo stages and constitutes the most scientifically developed line of inquiry tied to a constituent of this plant. However, this research concerns a synthetic or semi-synthetic form of the isolated compound, not oral administration of Stillingia sylvatica root. No human clinical trials of prostratin derived from Stillingia sylvatica root extract as a botanical supplement have been conducted. Evidence strength: preliminary, pre-clinical/in vitro only for the plant source itself.

6g. Constipation and Gastrointestinal Complaints

Traditional claim: Stillingia has been used in small doses as a laxative to alleviate constipation.

Evidence status: The laxative effect is pharmacologically plausible given the irritant nature of the diterpene esters on GI mucosa. However, no clinical trials of any design have been conducted for this indication. The same irritant mechanism responsible for the purported laxative effect also underlies significant safety concerns (see Safety section). Evidence is absent for clinical use.

7. Body Systems and Health Areas Associated with Traditional Use

• Lymphatic system: historically used as a lymphatic stimulant and for swollen glands (scrofula, strumous conditions).
• Skin: chronic skin eruptions, scrofulous skin conditions.
• Respiratory system: bronchitis, laryngitis, croup-like cough, ozaena.
• Gastrointestinal system: constipation, hemorrhoids; also as an emetic in large doses.
• Liver and biliary: liver disease and gallbladder disorders have been cited folk uses.
• Immune system / Blood: blood purification, alterative use.
• Musculoskeletal: Eclectic physicians recommended it for chronic rheumatism.
• Reproductive / Venereal: syphilis, strumous conditions, mercury poisoning from syphilis treatments.

8. Dosage Forms and Historical Dosages

No modern clinical trials have established evidence-based dosage recommendations. The following dosages are drawn from historical pharmaceutical texts and herbal monographs, reproduced as historical data only:

• Fluidextract (British Pharmaceutical Codex, 1911): Average dose: 2 mils (30 minims).
• Infusion: 1 teaspoon per cup of water, infused 25 minutes.
• Fresh-strength liquid extract (1:1.4): 10–30 drops 1–3 times per day.
• Tincture (contemporary herbalist recommendation, Stephen Buhner as cited by a supplier): 10 to 30 drops once per day.

According to the Eclectic tradition, the root must be prepared from the fresh root, as the dry root was considered inert by some practitioners, though the British Pharmaceutical Codex preparation used dried root with alcohol extraction.

It is important to note that modern phytochemical studies have identified irritant diterpene esters and other compounds in the roots, though contemporary medicinal applications remain limited and unverified by clinical research.

9. Safety Considerations

Queen's Delight has a well-documented toxicity profile that has caused major medical references to classify it as hazardous, particularly for internal use.

9a. Gastrointestinal and Mucosal Toxicity

When taken by mouth, Queen's Delight dried root is possibly unsafe. It contains chemicals that are irritating to the digestive tract and can cause nausea, vomiting, and diarrhea. Stillingia contains diterpene esters that cause mucosal irritation and skin eruptions.

Documented toxicity symptoms include vertigo, burning sensation on mucous membranes, diarrhea, nausea, vomiting, muscle ache, pruritus, skin eruptions, cough, fatigue, and sweating.

9b. Dermal Toxicity

The juice of the green root can cause skin inflammation and swelling. The root of Queen's Delight contains chemicals that are very irritating to the skin and thin tissues throughout the body, like the nose, mouth, and throat.

9c. Potential Carcinogenicity / Tumor Promotion

Modern research paints a concerning picture: the plant's diterpene esters are strongly irritating and may promote tumor growth in experimental models, and major medical references now classify it as unsafe for internal or topical use. The presence of phorbol-type diterpenes has led evaluators to warn of potential tumor-promoting and mutagenic effects, especially with repeated exposure. The diterpenes are thought to be carcinogenic and virus-activating.

9d. Systemic Toxicity

Systemic toxicity is of concern. Severe cases may involve cardiovascular effects such as tachycardia and collapse, reflecting systemic absorption of irritant and potentially cardiotoxic constituents.

9e. Pregnancy and Lactation

Stillingia is not for use during pregnancy or lactation. This product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

9f. Potential Drug Interactions

Because Queen's Delight is no longer recommended, interactions are inferred rather than thoroughly studied. Potential concerns include interactions with chemotherapeutic or immunomodulating agents: PKC-activating diterpenes like prostratin could, in theory, alter immune signaling or cancer cell behavior, complicating oncology care. With antiretroviral therapy: experimental use of prostratin analogs in HIV research raises concerns about unpredictable pharmacodynamic interactions between crude plant diterpenes and antiretroviral agents.

9g. Fresh versus Dried Root

Despite its popularity in early American herbalism, stillingia was known to cause side effects such as nausea, vomiting, burning in the throat, or diarrhea, particularly if used in high doses or in its fresh form. As a result, it was traditionally dried and combined with soothing demulcents to mitigate its intensity. The MSKCC and major pharmacological references note that the irritant diterpene ester content constitutes a primary and significant safety hazard regardless of preparation form.

10. Current Status in Herbal Practice

This herb is not often used in modern herbalism. Stillingia is still occasionally added to formulas used for the cleansing of the lymph and blood systems, and herbalists in the southeastern United States occasionally find uses for it with their patients. Today, Queen's Delight may still be found in older herbal formulas or in niche "detox" blends. Because of its toxicity and the absence of proven benefits, it is a herb where caution is essential.

References

• Memorial Sloan Kettering Cancer Center — Stillingia: Purported Uses, Evidence, and Safety
• Drugs.com Natural Products Database — Queen's Delight: Uses, Benefits & Dosage (referenced sources: Adolf et al. 1980, Duke 1992, Newall 1996, Harmanson 1882)
• WebMD Vitamins & Supplements — Queen's Delight Overview
• RxList — Queen's Delight: Health Benefits, Side Effects, Uses, Dose & Precautions
• Adolf W. & Hecker E. (1980). New irritant diterpene-esters from roots of Stillingia sylvatica L. (Euphorbiaceae). Tetrahedron Letters, 21, 2887–2890. (Abstract via ScienceDirect)
• LC–MS method for detecting prostratin in plant extracts and identification of a high-yielding population of Euphorbia fischeriana. Industrial Crops and Products (2012). (ScienceDirect)
• Prostratin Antagonizes HIV Latency by Activating NF-κB. Journal of Biological Chemistry (2004). (ScienceDirect)
• Korin et al. (2002). Effects of prostratin on T-cell activation and human immunodeficiency virus latency. Journal of Virology, 76(16), 8118–8123. (PubMed)
• Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. PLoS ONE (2017). (PMC)
• Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin. PLoS ONE (2009). (PMC)
• In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions. (PMC)
• Hecker E. — Cocarcinogenesis and tumor promoters of the diterpene ester type as possible carcinogenic risk factors. Journal of Cancer Research and Clinical Oncology (Springer)
• Tonantzitlolones from Stillingia lineata ssp. lineata as potential inhibitors of chikungunya virus. Phytochemistry Letters (2015). (ScienceDirect)
• Grokipedia — Stillingia sylvatica
• British Pharmaceutical Codex (1911) — Stillingia entry (Henriette's Herbal Homepage)
• Petersen F.J. (1905). Materia Medica and Clinical Therapeutics — Stillingia Sylvatica (Henriette's Herbal Homepage)
• Felter H.W. & Lloyd J.U. (1898). King's American Dispensatory — Stillingia (Henriette's Herbal Homepage)
• Smithsonian National Museum of American History — Stillingia sylvatica specimen (Eclectic Medicine collection)
• VitaLibrary — Queen's Delight Benefits and Side Effects: Evidence-Based Guide
• Caring Sunshine — Ingredient: Stillingia (referenced: Newall et al. 1996, Gruenwald et al. 1998)
• Plants For A Future (PFAF) — Stillingia sylvatica
• Wikipedia — Stillingia
• Gaia Herbs — Stillingia herbal reference (referenced: Gruenwald et al. PDR for Herbal Medicines 1998; Felter & Lloyd 1898; Tilgner 1999)
• Dr. Sharol Tilgner — Queen's Root monograph (excerpted from Herbal Medicine From the Heart of the Earth, 1999)
• Stallnaker A.G. (1876). Concentrated Vegetable Medicines [historical clinical notes on Stillingia tincture]. (PMC)